Find Clinical Trials

Inclusion Criteria: * age 19 years or older * diagnosis of type 2 diabetes * Black race (self-report) * receipt of care at one of the study sites with one or more visits to within the prior year * presence of elevated diabetes distress (score ≥2 on Diabetes Distress Scale indicating moderate-severe distress) * uncontrolled diabetes indicated by an elevated hemoglobin A1c (A1C) ≥8% Exclusion Criteria (Presence of any of the following criteria): * non-English speaker * current pregnancy * diagnosis of a severe psychiatric comorbidity including bipolar disorder, schizophrenia, or a history of psychosis

Inclusion Criteria: 1. Established diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) according to clinical notes 2. Fulfil Diagnostic and Statistical Manual of Mental Disorders (5th Edition) (DSM-5) criteria for current single or recurrent episodes of major depressive disorder of at least moderate severity but without psychotic features, as defined by the Mini Neuropsychiatric Interview 3. Aged 18 years or over 4. Use of contraception if female and of childbearing age. Female participants of childbearing age will require a negative serum/urine pregnancy test before starting the study and will also need to agree to use an acceptable form of contraception throughout the intervention period, e.g. oral contraceptive pill, long-acting reversible contraceptive 5. Able to provide written informed consent to enter the trial Exclusion Criteria: 1. Diagnosis of drug or alcohol dependence syndrome according to the General Practitioner (GP) summary care record or yes in answer to the question "have you ever been diagnosed with drug or alcohol dependence?" 2. Diagnosis of any personality disorder according to the GP summary care record or yes in answer to the question "have you ever been diagnosed with a personality disorder?" 3. Diagnosis of any dementia according to the GP summary care record or yes in answer to the question "have you ever been diagnosed with any form of dementia?" 4. Diagnosis of psychosis or schizophrenia according to the GP summary care record or yes in answer to the question "have you ever been diagnosed with psychosis or schizophrenia?" 5. Diagnosis of bipolar disorder according to the GP summary care record or yes in answer to the question "have you ever been diagnosed with bipolar disorder?" 6. Current active suicidal ideation on clinical assessment according to clinical judgment by a study consultant psychiatrist 7. Current treatment with mirtazapine, mianserin, trazodone or a monoamine oxidase inhibitor 8. Contraindications to the administration of mirtazapine, as per the current summary of product characteristics 9. Known allergy to mirtazapine or mianserin according to patient report or clinical notes 10. Non-registration with a GP or failure to consent to sharing of the GP summary care record and any psychiatric assessments held 11. Currently enrolled in another drug trial or psychological therapy trial 12. Currently hospitalised for the treatment of IBD 13. Currently being prescribed a course of budesonide or reducing course of prednisolone for IBD 14. Planned change in IBD treatment within the next 12 weeks according to clinical notes or answer yes to the question: "are you expecting any change in your IBD treatment to take place in the next 12 weeks?"

Inclusion Criteria: * women diagnosed with primary BC, eligible for surgical resection of the tumor according to national and international guidelines. age between 18 and 70 years; newly diagnosed breast neoplasms, tumor size of at least 1.5 cm diameter. Exclusion Criteria: breast cancer diagnosed during pregnancy, neoadiuvant chemotherapy

Inclusion Criteria: * Age: younger than 6 years * Exposed to second-hand smoke at home (at least one parent smoking) * German speaking parent * All sex and ethnic backgrounds * Signed informed consent form from parent * Children live/grow-up in the same household as the parental participant * Referred by a health care professional (e.g. physician, midwife, nurse, other professions) Exclusion Criteria: * Participation in another study/trial targeting similar outcomes * Participation in an active smoking cessation programme

Inclusion Criteria: * Tumour, Node, Metastasis stage (TNM) = dimension up to 15 mm as measured by breast ultrasound, MRI, Mammography, Node negative, absence of distant metastasis * Unifocality * All invasive cancer, except lobular * Biology= luminal A and luminal B\* (Estrogen Receptor (ER) positive/human epidermal growth factor receptor-2 (HER2)negative) (Documented estrogen receptor (ER)-positive tumor assessed locally and defined as ≥10% of tumor cells stained positive. Documented HER2-negative tumor (in accordance to 2018 American Society of Clinical Oncology guidelines, as determined per local assessment) * Any grade (G) * Radiological detection= breast ultrasound, MRI, Mammography * Tumor site= not located superficially (≥1 cm from the skin plane) * Breast size= any, appropriate for the procedure in relation to ultrasound examination * Referral to breast cryoablation by a multidisciplinary tumor board * Planned treatment with cryoablation using IceCure (TM-trade mark) system * Informed consent \*Luminal B and G3 BC: previous specific patients' selection and Oncotype Dx \[31\] on cancer tissue from needle biopsy before procedure and eventual Prediction Analysis of Microarray 50 (PAM50) test. Exclusion Criteria: * Plurifocality * Invasive lobular breast cancer * HER2 overexpressed or Triple Negative Breast Cancer (TNBC) * tumor dimension \>15 mm * Node positive * post NeoAdjuvant ChemoTherapy (NACT) breast cancer * \<50 years * Presence of intraductal component (DCIS) * Absence of psychological compliance in understanding and adhering to rationale of the study * Inability to perform MRI * Breast augmentation with implants

Inclusion Criteria: * Age 18-75 years (inclusive); male or non-pregnant female. * Diagnosed with cirrhosis and associated complications of portal hypertension (such as esophageal and gastric variceal bleeding, refractory ascites), and meeting the consensus recommendations for TIPS indications (see Appendix 5). * Participants must understand the purpose of the trial, voluntarily participate, sign an informed consent form, and be willing to complete the follow-up according to the project requirements. Exclusion Criteria: * Severe right heart failure, congestive heart failure (LVEF \< 40%), or severe valvular heart dysfunction. * Uncontrolled systemic infection or inflammation. * Persistent moderate to severe pulmonary hypertension after treatment (tricuspid regurgitant peak velocity \> 3.4 m/s or pulmonary artery systolic pressure \> 50 mmHg). * Patients in hepatic encephalopathy coma or comatose phase (West Haven Criteria Stage III, IV). * Severe liver dysfunction, Child-Pugh score \> 13, or MELD score \> 18. * Serum creatinine (Scr) \> 178 umol/L or on dialysis. * Stage IIIa or higher liver malignancy. * Budd-Chiari syndrome, hepatic veno-occlusive disease, or obstructive cholestasis. * Polycystic liver disease. * Unrectifiable coagulopathy (INR \> 5 or PLT count \< 20 x 10\^9/L). * Main portal vein thrombosis occupying \> 50% of the lumen area or cavernous transformation of the portal vein. * Previous TIPS procedure or planned liver transplantation within a year. * Allergy to contrast agents or nickel-titanium alloys. * Life expectancy less than 1 year. * Participation in other drug or medical device clinical trials within three months before screening. * Other conditions deemed by the researcher as unsuitable for participation in this clinical trial.

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Aged 3 to 18 as of first recruitment * Diagnosed with poorly controlled asthma * Asthma control test score below * Caregiver able operate a mobile application * Has access high-speed wireless internet (WiFi) at home * Able to read English * Agreement to adhere to medical device use regimen throughout the study duration Exclusion Criteria: * Known allergy to silicone, gold, or zinc * Abnormal skin conditions on chest * Sleep apnea diagnosis

Inclusion Criteria: * Online consent for participation * Adequate proficiency in the German language, encompassing both reading and comprehension skills * Ownership of a smartphone, compatible with either Android or iOS operating systems, and access to the Internet For individuals in the clinical group with current depressive disorders: * Currently meeting the DSM-5 criteria for a mild or moderate major depressive episode, or persistent depressive disorder Exclusion Criteria: * Current severe substance use disorder * Acute suicidality * Current severe major depressive episode * Lifetime bipolar disorder * Lifetime psychotic disorders For the control group, additional exclusion criteria include: * Meeting the DSM-5 criteria for a major depressive episode within the last 12 months * History of severe major depressive episodes * Recurrent depressive disorder * History of persistent depressive disorder * Current treatment (psychotherapy, pharmacotherapy) for depressive symptoms

Inclusion Criteria: 1. Aged between 40 and 70 years old; 2. Patients with hypertension or diabetes; 3. Permanent residents of the county where the research is conducted; 4. Already signed up with the family doctor team in the township where the research is located. Exclusion Criteria: 1. Unable to independently carry out the interventions required for the study; 2. Residing far from the village or township health center where the research is located, making it difficult to cooperate with visits; 3. Patients who refuse to participate; 4. Patients with comorbidities such as cancer that may interfere with the study visits or intervention effects; 5. Pregnant or lactating women

Inclusion Criteria: * Women aged between 45 and 74 years * Asymptomatic * Signed informed consent form before starting any study activity * Average risk of BC (every woman except those with know BRCA1, 2, TP53, and/or previous BC) * Mammographic test, either 2D FFDM or 3D Digital Breast Tomosynthesis (DBT) (collecting oblique mediolateral projection \[MLO\] of the right breast, craniocaudal projection \[CC\] of the right breast, MLO projection of the left breast, CC projection of the left breast), performed within the past month with available results or planned to be performed in the same day of the MammoWave test or in the subsequent days * Spontaneous willingness to comply with CIP and recommendations Exclusion Criteria: * Woman with breast prostheses * Women with symptoms or some sign of suspected BC * Women with BRCA1, 2, TP53 or previous BC * Pregnant women * Women who do not have mammographic manifestation of the tumor (known occult breast tumor with only axillar manifestation) * Women with breast size larger than the largest MammoWave cup size

Inclusion Criteria: 1. Current major depressive episode according to the DSM-5 diagnostic criteria evaluated with the DIAMOND diagnostic interview, that is considered to be the primary diagnosis. 2. Sore of 14 or higher on Becks Depression Inventory-II (BDI-II) that measures severity of symptoms of depression past 2 weeks. 3. Participants are between 18 and 65 years of age at start of study. 4. Satisfactory understanding of the Icelandic language to complete measures in the study. 5. Completion of pre-treatment assessment that includes 2 visits to researchers and a 6-day ecological momentary assessment. Exclusion Criteria: 1. Current or past manic or hypomanic episodes according to the DSM-5 diagnostic criteria evaluated with the DIAMOND diagnostic interview. 2. Current or past psychotic disorders according to the DSM-5 diagnostic criteria evaluated with the DIAMOND diagnostic interview. 3. Presence of substance abuse within the last 12 months according to the DSM-5 diagnostic criteria evaluated with the DIAMOND diagnostic interview. 4. Presence of active and serious suicidal thoughts or a suicidal attempt in the previous 2 months. 5. Unstable medical treatment for depression (type of drug and/or dosing) during past two months at pre-treatment assessment. 6. Recent psychotherapy within the past month at pre-treatment assessment or active psychotherapy during study participation. 7. Cognitive impairments or severe physical illness.

Inclusion Criteria: * self-identify as Chinese American; * be above 18 years old; * have a diagnosis of Type 2 diabetes (T2D) in the medical record; * have had an appointment with a physician for routine T2D care within the past 12 months; * have a most recent HbA1c of at least 7%; * be willing to receive brief videos regarding T2D management; and * possess a smartphone or, if they do not have one, be willing and able to use a study smartphone. Exclusion Criteria: * unable or unwilling to provide informed consent; * unable to participate meaningfully in the intervention (e.g., uncorrected sight and hearing impairment); * unwilling to accept randomization assignment; * is pregnant, plans to become pregnant in the next 6 months, or becomes pregnant during the study; or * is breastfeeding (e.g., they may have potential dietary restrictions).

Main key inclusion criteria: * Current diagnosis of AN according to fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) confirmed with Structured Clinical Interview for DSM-5 (SCID-5) * BMI \> 13 kg/m2; BMI ≤ 18 kg/m2; body weight ≥ 35 kg * Hospitalisation in the Eating Disorders Unit, Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital of Zurich * Ability to understand German language * Age range: 17 - 65 years * Depressive symptoms: HAMD-17 ≥ 8 * Negative urine pregnancy test, non-lactating and double birth control * Informed Consent as documented by signature Main key exclusion criteria: * Illicit drug intake within last month; current alcohol use disorder * Severe psychiatric and/or severe somatic comorbidities; f. e. lifetime diagnosis of schizophrenia, bipolar disorder, inflammatory bowel disorders, diabetes mellitus, autoimmune disorders, pancreatitis, neurological disorders, cancer including lymphoma * Acute suicidality or current serious non-suicidal self-injury

Inclusion Criteria: * 1\) Be between the ages of 12-25; * 2\) is right-handed on the Edinburgh Handedness Inventory; * 3\) 2-4 of the 9 depressive symptoms defined by the American Diagnostic and Statistical Manual of Diseases, Fifth Edition (DSM-5), lasting more than 1 week; or more than 5 depressive symptoms lasting more than 1 week but less than 2 weeks (i.e., not meeting criteria for a major depressive episode) (by DSM-5 Clinical Semi-Definitive Interview (K-SADS-PL) (Gilbody et al., 2017, JAMA); * 4\) Hamilton Depression Scale (HAMD-24) 24 points≥ 8 points, \&lt; 24 points; * 5\) Gender is not limited; * 6\) Subjects and their families voluntarily participate and sign the informed consent form. Exclusion Criteria: * 1\) Individuals with the following diagnoses according to DSM-5: psychiatric disorders due to organic diseases, substance-related and addictive disorders, neurodevelopmental disorders, schizophrenia spectrum and other psychotic disorders, bipolar disorder (assessed by K-SADS-PL); * 2\) Have two or more DSM-V-defined manic symptoms for 4 days but do not meet the criteria for hypomania or meet the DSM-V defined criteria for hypomanic symptoms for only 2-3 days; * 3\) Severe or unstable physical illness; * 4\) have a moderate or higher risk of suicide (as assessed by the Columbia Suicide Severity Scale); * 5\) Received transcranial direct current stimulation in the past three months (continuous intervention time: \&gt;2 weeks); * 6\) Contraindications to transcranial direct current stimulation, such as brain implants, personal or family history of epilepsy; * 7\) Magnetic resonance scanning is contraindicated, such as in vivo metal implants.

Inclusion Criteria: 1. Female patients with early-stage breast cancer between the ages of 18 and 70. 2. Breast cancer was confirmed by histology or biopsy. 3. Breast-conserving surgery or multifocal breast cancer or large unifocal breast cancer (\<5cm) can be accepted. 4. After neoadjuvant therapy, large monofocal carcinoma (\>5 cm) confined to the breast shrunk to \<5 cm. 5. No chest wall, cutaneous or NAC invasion (including Paget's disease). 6. Mild to moderate breast sagging, and the patient has the willingness to undergo autologous reconstruction of the latissimus dorsi. 7. There is no need to obtain additional back skins. 8. Willing to participate and able to complete follow-up and evaluation during the study. Exclusion Criteria: 1. Patients with advanced breast cancer (stage III and above) or metastatic breast cancer or inflammatory breast cancer. 2. The risk of recurrence is expected to be high. 3. History of thoracic and dorsal vascular injury. 4. Patients with severe heart, lung, or liver disease who cannot withstand surgery and anesthesia. 5. Patients with active infection or severe immune system disease. 6. Patients with severe allergic reactions to materials related to latissimus dorsi muscle flap transplantation. 7. Patients with other major surgeries or reconstructive surgeries planned for the near future. 8. Patients with cognitive dysfunction or psychiatric disorders who cannot understand and cooperate with the requirements of the study. 9. Patients who refuse to participate in the study or are unable to complete follow-up and evaluation during the study.

Inclusion Criteria: * healthy women, age 18-40 years, \<16 weeks' gestation, with singleton pregnancy; women (BMI:18.5-45.0), sedentary, cleared by their obstetric provider. Exclusion Criteria: * pre-existing chronic conditions such as HIV, lupus, etc.; taking medicines that affect fetal development; and/or lack of telephone or email contact information).

Inclusion Criteria: 1. Patients aged 18 to 75 years, inclusive, from any nationality. 2. Patients diagnosed with early-stage breast cancer. 3. Eastern Cooperative Oncology Group performance status ranging from 0 to 2. 4. All patients must undergo highly emetogenic chemotherapy (HEC). 5. Adequate organ function. 6. Adequate contraception required for premenopausal women. Exclusion Criteria: 1. Scheduled to undergo chemotherapy between days 2 to 4 following HEC. 2. Received or is planned to receive abdominal radiation therapy within 1 week before Day 1 in cycle 1. 3. Significant medical or psychological conditions. 4. Presents with symptomatic primary or metastatic central nervous system malignancy causing nausea and/or vomiting. 5. Experiencing ongoing vomiting or nausea of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE). 6. Any known allergies to the study drug, antiemetics, or dexamethasone. 7. Patients who have fear of electroacupuncture stimulation or are allergic to stainless steel needles. 8. Received acupuncture treatments for any conditions within 8 weeks prior to HEC.

Inclusion Criteria: * Visually significant cataract planned for surgery * Mild to moderate open-angle glaucoma, including pigmentary glaucoma and pseudoexfoliation glaucoma * Mild stage glaucoma includes glaucomatous optic neuropathy and visual field mean deviation better than -6.0 dB, with no points in the central 5 degrees \<15 dB * Moderate stage glaucoma includes: 1) glaucomatous optic neuropathy and visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5 degree points \<15 dB or 2) mean deviation -12.0 dB or better with 1 central 5 degree point \<15 dB * Medicated IOP between 10 to 31 mm Hg, inclusive, at time of decision for surgery * Willing and able to understand and provide informed consent * Willing and able to attend postoperative examinations per protocol schedule Exclusion Criteria: * Prior argon laser trabeculoplasty, laser peripheral iridotomy, incisional glaucoma surgery, or cyclophotocoagulation * Selective laser trabeculoplasty within 90 days of study enrollment * Iridotrabecular contact for 180 degrees or greater * Peripheral anterior synechiae in nasal or inferior angle * Best corrected visual acuity worse than 20/200 * Phacodonesis on pre-operative examination * Vitreous in anterior chamber on pre-operative examination * Nanophthalmos * Anti-platelet and anticoagulant medications other than aspirin 81mg daily * Active treatment for another ophthalmic condition in either eye (e.g., anti-VEGF injections, steroids for corneal transplant) * Abnormality in study eye that could affect tonometry * Glaucoma diagnosis other than the above * Normal tension glaucoma * Conditions that can cause elevated episcleral venous pressure (e.g., Sturge-Weber syndrome, Graves disease, retrobulbar tumor) * History of uveitis in either eye * Inability to complete gonioscopy examination * Use of oral steroids within 90 days or anticipated use of oral steroids * Oral medications that can affect IOP, including oral carbonic anhydrase inhibitors such as acetazolamide and methazolamide * History of steroid-associated IOP elevation * Medically unfit for attending planned study visits * Involvement in another interventional research study

Inclusion Criteria: 1. \- Type 2 DM. 2. \- HbA1c \> 53 mmol/l (7.0 %, estimated average glucose (eAG) 8.6 mmol/l). 3. \- Contact to diabetes clinic for ≥ 6 months. 4. \- Insulin treatment ≥ 12 months. 5. \- Basal insulin and bolus insulin at least for one meal every day. 6. \- Bolus insulin is insulin aspart. 7. \- Stable insulin treatment (change 10 % or less) and no introduction of other antihyperglycemic agents (oral or GLP1 analogue) for at least 2 months before randomization. 8. \- Considered to be technically and intellectually capable of using isCGM and smart pen. 9. \- Can communicate in Danish. 10. \- Informed consent including acceptance to share glucose data from the Libreview platforms. 11. \- The patient has a smart phone suitable for Libre and NOVOpen6 data registration. Exclusion Criteria: 1. \- Individual goal for HbA1c is reached (even if \> 53 mmol/mol), i.e. relaxed treatment goals as relevant for fragile patients with severe diabetic complications or comorbidities. 2. \- Fasting C-peptide \< 370 pmol/l. 3. \- Actual treatment with CGM or previous use of CGM for more than four weeks or \< 6 months before recruitment. No actual or previous use of connected pen. 4. \- One or more severe hypoglycemic episode (assistance of third party) within the previous 12 months. 5. \- Considered unable to participate due to frequent cancellation of appointments. 6. \- Ongoing steroid treatment or expected intermittent treatment of more than 14 days' duration. 7. \- Pregnant or planning pregnancy. 8. \- Participating in other trials. 9. \- Clinical conditions interfering with interpretation of HbA1c (phlebectomy, bleeding or haemolytic disorders, erythropoietin treatment, known haemoglobin variants, etc.) or continuous intake of high dose of vitamin C (\> 1000 mg), salicylic acid (650 mg daily), Salazopyrin or Dapsone. 10. \- Allergic reaction to the adhesive used in the isCGM.

Inclusion Criteria: * Female with native breasts and localized breast cancer who are status post-lumpectomy surgery, will receive whole breast radiation therapy with/without nodal irradiation, with standard fractionation or moderate hypofractionation * Age \>= 18 years * Ability to understand and the willingness to sign a written informed consent in English or Spanish Exclusion Criteria: * Underlying diagnosis of chronic inflammatory illness or collagen vascular disorder, e.g. scleroderma, lupus, rheumatoid arthritis, fibromyalgia as these conditions may significantly affect the likelihood and magnitude of radiation related toxicity * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Inability to provide written informed consent in English or Spanish * Patients receiving ultra-hypofractionation, and/or partial breast or chest wall radiation therapy are excluded